Critical step towards new treatment option
Exciting new research has been published by the Pancreatic Cancer UK Grand Challenge team at Barts Cancer Institute
Our open letter to Jo Churchill, Cancer Minister for England
An open letter to Jo Churchill, the Cancer Minister, raising our concerns about how COVID-19 is impacting pancreatic cancer treatment and care.
Facebook Champion Volunteer
Learning and development
2020 has done a very good job of derailing everyone’s plans. That includes our grand plan to deliver an assortment of face-to-face training and events across the UK to connect, develop and inspire more pancreatic cancer health professionals. Bur we embraced the digital world and adapted our events for a virtual audience.
PCAM 2020: A year to remember
2020 is a year to remember in so many ways, but November 2020 will definitely go down in history as the year we saw the pancreatic cancer community rally together to make an impact like never before.
We are very sorry to learn that Catherine Wines, co-founder of World Remit and a supporter of Pancreatic Cancer UK has passed away from pancreatic cancer.
Spearheading the Less Survivable Cancers Taskforce
Pancreatic Cancer survival rates have not changed in 50 years. We knew that if we were to make the decision makers listen, we would have to make our voices louder.
Our Support Line turns 10
Here we interview Jeni, our longest standing member of the Specialist Nurse Team at Pancreatic Cancer UK. She’s witnessed radical changes in the running of the service over the last 10 years.
Exciting research hope – our Grand Challenge
Our Head of Research, Chris Macdonald caught up with Professor John Marshall, Barts Cancer Institute, to get an update on the Pancreatic Cancer UK Grand Challenge award
Information about the supply of Creon 25,000
Specialist nurses Emma and Lynne, provide information following an update in May 2020 about the supply of Creon 25,000
A small step that gives our campaigns tremendous power
We analyse publicly available data from cancer registries to identify the key issues that impact diagnosis, care and treatment of people with pancreatic cancer, and use this data to evidence and inform our campaigns.
Information about the supply of Creon 40,000
The company that makes Creon will not be making Creon 40,000 from June 2019.